ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a California-based company with 772 employees that specializes in developing and commercializing pharmaceutical solutions for neurological and psychiatric disorders. They have generated $493.1 million in revenue. Acadia Pharmaceuticals is focused on bringing much-needed treatments to patients suffering from a range of debilitating conditions. Their portfolio includes approved therapies for hallucinations and delusions associated with Parkinson's disease psychosis and Rett syndrome. The company is also actively engaged in clinical trials investigating new treatments for negative symptoms of schizophrenia, Alzheimer's disease psychosis, and neuropsychiatric symptoms in central nervous system disorders. A key differentiator for Acadia Pharmaceuticals is its dedication to focusing on underserved patient populations affected by neurological and psychiatric diseases. Their commitment to research and development drives the creation of innovative therapies that aim to improve the quality of life for these individuals. For more information about Acadia Pharmaceuticals, their research programs, or career opportunities, please visit their website at acadia.com.